Format

Send to

Choose Destination
Diagn Microbiol Infect Dis. 2019 Feb 21. pii: S0732-8893(18)30773-9. doi: 10.1016/j.diagmicrobio.2019.02.013. [Epub ahead of print]

Emergence of a multidrug-resistant clinical isolate of Escherichia coli ST8499 strain producing NDM-13 carbapenemase in the Republic of Korea.

Author information

1
Infectious Diseases Team, Seoul Metropolitan Government Research Institute of Public Health and Environment, Gyeonggi-do, Republic of Korea. Electronic address: babygogs@seoul.go.kr.
2
Infectious Diseases Team, Seoul Metropolitan Government Research Institute of Public Health and Environment, Gyeonggi-do, Republic of Korea.
3
Environmental Health Division, Seoul Metropolitan Government, Seoul, Republic of Korea.
4
Division of Bacterial Diseases, Korea Centers for Diseases Control & Prevention, Chungcheongbuk-do, Republic of Korea.
5
Division of Vaccine Research, Korea Centers for Diseases Control & Prevention, Chungcheongbuk-do, Republic of Korea.

Abstract

We described a carbapenem-resistant Escherichia coli ST8499 strain producing New Delhi metallo-β-lactamase-13 (NDM-13) from patient in Korea. The isolate exhibited multidrug resistance, but remained susceptible to colistin and tigecycline. The blaNDM-13 gene was located on a 130-kb self-transmissible plasmid. This is the first report of NDM-13 carbapenemase in Korea.

KEYWORDS:

CRE; Carbapenemase; E. coli ST8499; Multidrug resistance; NDM-13

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center